510(k) device
HemosIL Factor XII Deficient Plasma
Instrumentation Laboratory CO · Plasma, Coagulation Factor Deficient (GJT, Class II) · First FDA decision Jan 14, 2003, newest Mar 22, 2018Anemia, clotting and blood disorders
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
10
510(k) pathway
Device trials
1
Naming "HemosIL"
MAUDE reports
59
Brand "HemosIL", since 2015
PubMed studies
181
Mentioning "HemosIL"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing HemosIL Factor XII Deficient Plasma
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 10 decisions filed under this name.
K180486 · Decided Mar 22, 2018 · 27 days after receipt
Device type: Plasma, Coagulation Factor Deficient (GJT) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "HemosIL", any status and sponsor, newest update first.
- Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic PurpuraActive, not recruiting
Fundación Española de Hematología y HemoterapíaAcademic, hospital or other
NCT05046717 · 500 participants (planned) · Start Oct 13, 2022 · Primary completion Nov 14, 2025
Device: ADAMTS13 Activity Assays · For: Acquired Thrombotic Thrombocytopenic Purpura
Sites: Coimbra, Portugal; A Coruña, Spain; Barcelona, Spain · 6 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "HemosIL", and for the whole product code for context.
This brand
59 reports: 50 malfunction, 6 injury, 2 death
Whole product code GJT
11 reports: 11 malfunction, 0 injury, 0 death
Newest reports for this brand
- HemosIL AcuStar HIT-IgG (PF4-H)Malfunction
Instrumentation Laboratory Co.
1217183-2026-00033 · Received Oct 27, 2026 · Event dated Jul 16, 2026
Device type: Platelet Factor 4 Radioimmunoassay (LCO)
Device problem as coded: False Negative Result
Patient problem as coded: Insufficient Information
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "HemosIL"[tiab]. The summary above synthesizes these.
- Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.
Ikeda K, Tachibana H · J Arrhythm · 2016
- HemosIL VWF:GPIbR Assay Has a Greater Sensitivity than VWF:RCo Technique to Detect Acquired von Willebrand Syndrome in Myeloproliferative Neoplasms.
Laporte P, Tuffigo M, Ryman A, et al. · Thromb Haemost · 2022
- Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure.
Schönborn L, Esteban O, Wesche J, et al. · Blood · 2023Research Support, Non-U.S. Gov't
- Profile of Instrumentation Laboratory's HemosIL® AcuStar HIT-Ab(PF4-H) assay for diagnosis of heparin-induced thrombocytopenia.
Nagler M, Cuker A · Expert Rev Mol Diagn · 2017Review
- Multicentric evaluation of the new HemosIL Acustar® chemiluminescence ADAMTS13 activity assay.
Pascual C, Nieto JM, Fidalgo T, et al. · Int J Lab Hematol · 2021Evaluation Study, Multicenter Study
- Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia.
Marashi-Sabouni Z, Vayne C, Ibrahim-Kosta M, et al. · J Thromb Thrombolysis · 2021
- Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay.
Favresse J, Lardinois B, Chatelain B, et al. · Thromb Haemost · 2018Comparative Study, Evaluation Study
- Optimization of laboratory diagnosis of heparin-induced thrombocytopenia using HemosIL-AcuStar-HIT-IgG assay.
Tucker CM, Rhoades R, Sharma R, et al. · Lab Med · 2024
- HemosIL D-dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study.
Scarvelis D, Palareti G, Toulon P, et al. · J Thromb Haemost · 2008Letter, Research Support, Non-U.S. Gov't
- Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT-ab (PF4-H) for the diagnosis of heparin-induced thrombocytopenia.
Jourdy Y, Nougier C, Rugeri L, et al. · Int J Lab Hematol · 2015Research Support, Non-U.S. Gov't
- Diagnosis of Thrombotic Thrombocytopenic Purpura by ADAMTS13 Activity Quantification.
Dimopoulos K, Philips M, Goetze JP · J Appl Lab Med · 2022
- Analytical comparison of AxSYM, HemosIL DD HS and Innovance D-dimer immunoassays with the Vidas D-dimer.
Salvagno GL, Lippi G, Manzato F, et al. · Int J Lab Hematol · 2009Comparative Study, Letter
Other devices of this type
Also filed under product code GJT.
- CRYOcheck Factor VIII Deficient Plasma with VWFPrecision Biologic, Inc. · 510(k) 2023
- Nofact IXR2 Diagnostics, Inc. · 510(k) 2011
- Nofact VIIIR2 Diagnostics, Inc. · 510(k) 2011
- Diapharma Factor X KitDiapharma Group, Inc. · 510(k) 2004
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.